Cannon, TD, Kaprio, J, Lonnqvist, J, Huttunen, M, Koskenvuo, M. The genetic epidemiology of schizophrenia in a Finnish twin cohort. A population-based modeling study. Arch Gen Psychiatry. 1998; 55(1): 67–74.
Insel, TR. Rethinking schizophrenia. Nature. 2010; 468(7321): 187–193.
Saha, S, Chant, D, McGrath, J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007; 64(15): 1123–1131.
Joukamaa, M, Heliovaara, M, Knekt, P, Aromaa, A, Raitasalo, R, Lehtinen, V. Mental disorders and cause-specific mortality. Br J Psychiatry. 2001; 179: 498–502.
Chen, DC, Du, XD, Yin, GZ, et al. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia: relationships with clinical phenotypes and cognitive deficits. Psychol Med. 2016; 46(15): 3219–3230.
Perry, BI, McIntosh, G, Weich, S, Singh, S, Rees, K. The association between first-episode psychosis and abnormal glycaemic control: systematic review and meta-analysis. Lancet Psychiatry. 2016; 3(11): 1049–1058.
Lizano, PL, Keshavan, MS, Tandon, N, et al. Angiogenic and immune signatures in plasma of young relatives at familial high-risk for psychosis and first-episode patients: a preliminary study. Schizophr Res. 2016; 170(1): 115–122.
Spelman, LM, Walsh, PI, Sharifi, N, Collins, P, Thakore, JH. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med. 2007; 24(5): 481–485.
Rettenbacher, MA. Disturbances of glucose and lipid metabolism during treatment with new generation antipsychotics. Curr Opin Psychiatry. 2005; 18(2): 175–179.
Newcomer, JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007; 68(Suppl 1): 20–27.
Ryan, MC, Collins, P, Thakore, JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003; 160(2): 284–289.
Venkatasubramanian, G, Chittiprol, S, Neelakantachar, N, et al. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry. 2007; 164(10): 1557–1560.
Cohn, TA, Remington, G, Zipursky, RB, Azad, A, Connolly, P, Wolever, TM. Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry. 2006; 51(6): 382–386.
Bellivier, F. Schizophrenia, antipsychotics and diabetes: genetic aspects. Eur Psychiatry. 2005; 20(Suppl 4): S335–339.
Gough, SC, O’Donovan, MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J Psychopharmacol. 2005; 19(6 Suppl): 47–55.
Lin, PI, Shuldiner, AR. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr Res. 2010; 123(2–3): 234–243.
Van Lieshout, RJ, Voruganti, LP. Diabetes mellitus during pregnancy and increased risk of schizophrenia in offspring: a review of the evidence and putative mechanisms. J Psychiatry Neurosci. 2008; 33(5): 395–404.
Fernandez-Egea, E, Bernardo, M, Parellada, E, et al. Glucose abnormalities in the siblings of people with schizophrenia. Schizophr Res. 2008; 103(1–3): 110–113.
Fernandez-Egea, E, Miller, B, Bernardo, M, Donner, T, Kirkpatrick, B. Parental history of type 2 diabetes in patients with nonaffective psychosis. Schizophr Res. 2008; 98(1–3): 302–306.
Mukherjee, S, Schnur, DB, Reddy, R. Family history of type 2 diabetes in schizophrenic patients. Lancet. 1989; 1(8636): 495.
Enez Darcin, A, Yalcin Cavus, S, Dilbaz, N, Kaya, H, Dogan, E. Metabolic syndrome in drug-naive and drug-free patients with schizophrenia and in their siblings. Schizophr Res. 2015; 166(1–3): 201–206.
Foley, DL, Mackinnon, A, Morgan, VA, et al. Common familial risk factors for schizophrenia and diabetes mellitus. Aust N Z J Psychiatry. 2016; 50(5): 488–494.
Hsu, JH, Chien, IC, Lin, CH, Chou, YJ, Chou, P. Incidence of diabetes in patients with schizophrenia: a population-based study. Can J Psychiatry. 2011; 56(1): 19–26.
Carliner, H, Collins, PY, Cabassa, LJ, McNallen, A, Joestl, SS, Lewis-Fernandez, R. Prevalence of cardiovascular risk factors among racial and ethnic minorities with schizophrenia spectrum and bipolar disorders: a critical literature review. Compr Psychiatry. 2014; 55(2): 233–247.
Bai, YM, Su, TP, Chen, MH, Chen, TJ, Chang, WH. Risk of developing diabetes mellitus and hyperlipidemia among patients with bipolar disorder, major depressive disorder, and schizophrenia: a 10-year nationwide population-based prospective cohort study. J Affect Disord. 2013; 150(1): 57–62.
Liao, CH, Chang, CS, Wei, WC, et al. Schizophrenia patients at higher risk of diabetes, hypertension and hyperlipidemia: a population-based study. Schizophr Res. 2011; 126(1–3): 110–116.
Li, M, Fan, YL, Tang, ZY, Cheng, XS. Schizophrenia and risk of stroke: a meta-analysis of cohort studies. Int J Cardiol. 2014; 173(3): 588–590.
Lin, HC, Chen, YH, Lee, HC, Lin, HC. Increased risk of acute myocardial infarction after acute episode of schizophrenia: 6 year follow-up study. Aust N Z J Psychiatry. 2010; 44(3): 273–279.
Cohn, T, Prud’homme, D, Streiner, D, Kameh, H, Remington, G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004; 49(11): 753–760.
Kuo, CF, Grainge, MJ, Valdes, AM, et al. Familial aggregation of systemic lupus erythematosus and coaggregation of autoimmune diseases in affected families. JAMA Intern Med. 2015; 175(9): 1518–1526.
Chen, MH, Hsu, JW, Huang, KL, et al. Sexually transmitted infection among adolescents and young adults with attention-deficit/hyperactivity disorder: a nationwide longitudinal study. J Am Acad Child Adolesc Psychiatry. 2018; 57(1): 48–53.
Chen, MH, Lan, WH, Hsu, JW, et al. Risk of developing type 2 diabetes in adolescents and young adults with autism spectrum disorder: a nationwide longitudinal study. Diabetes Care. 2016; 39(5): 788–793.
Chen, MH, Pan, TL, Li, CT, et al. Risk of stroke among patients with post-traumatic stress disorder: nationwide longitudinal study. Br J Psychiatry. 2015; 206(4): 302–307.
Cheng, CM, Chang, WH, Chen, MH, et al. Co-aggregation of major psychiatric disorders in individuals with first-degree relatives with schizophrenia: a nationwide population-based study. Mol Psychiatry. 2018; 23(8): 1756–1763.
Liu, CY, Hung, YT, Chuang, YL, Chen, YJ, Weng, WS, Liu, JS. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Management (Chin). 2006; 4: 1–22.
Andreassen, OA, Djurovic, S, Thompson, WK, et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet. 2013; 92(2): 197–209.
Hansen, T, Ingason, A, Djurovic, S, et al. At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol Psychiatry. 2011; 70(1): 59–63.
Liu, Y, Li, Z, Zhang, M, Deng, Y, Yi, Z, Shi, T. Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis. BMC Med Genomics. 2013; 6(Suppl 1): S17.
McDermott, E, de Silva, P. Impaired neuronal glucose uptake in pathogenesis of schizophrenia—can GLUT 1 and GLUT 3 deficits explain imaging, post-mortem and pharmacological findings? Med Hypotheses. 2005; 65(6): 1076–1081.
Perez-Iglesias, R, Mata, I, Pelayo-Teran, JM, et al. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naive population. Schizophr Res. 2009; 107(2-3): 115–121.
Buse, JB. Metabolic side effects of antipsychotics: focus on hyperglycemia and diabetes. J Clin Psychiatry. 2002; 63(Suppl 4): 37–41.
Haddad, PM. Antipsychotics and diabetes: review of non-prospective data. Br J Psychiatry Suppl. 2004; 47: S80–86.
Sernyak, MJ, Leslie, DL, Alarcon, RD, Losonczy, MF, Rosenheck, R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002; 159(4): 561–566.
McIntyre, RS, McCann, SM, Kennedy, SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 2001; 46(3): 273–281.
Johnson, DE, Yamazaki, H, Ward, KM, et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. Diabetes. 2005; 54(5): 1552–1558.
Bener, A, Al-Hamaq, AO, Dafeeah, EE. A two fold risk of metabolic syndrome in a sample of patients with schizophrenia: do consanguinity and family history increase risk? Diabetes Metab Syndr. 2014; 8(1): 24–29.
Ukkola, O, Sun, G, Bouchard, C. Insulin-like growth factor 2 (IGF2) and IGF-binding protein 1 (IGFBP1) gene variants are associated with overfeeding-induced metabolic changes. Diabetologia. 2001; 44(12): 2231–2236.
Sicras-Mainar, A, Maurino, J, Ruiz-Beato, E, Navarro-Artieda, R. Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia. Neuropsychiatr Dis Treat. 2015; 11: 51–57.
Saatcioglu, O, Kalkan, M, Fistikci, N, Erek, S, Kilic, KC. Relationship between metabolic syndrome and clinical features, and its personal-social performance in patients with schizophrenia. Psychiatr Q. 2016; 87(2): 265–280.
Ogawa, M, Miyamoto, Y, Kawakami, N. Factors associated with glycemic control and diabetes self-care among outpatients with schizophrenia and type 2 diabetes. Arch Psychiatr Nurs. 2011; 25(1): 63–73.